title: [The role of clevidipine in hypertension management: clinical results].
abstract: The prevalence of hypertension in general population is from 30% to 45%(.) Anesthesiologists frequently deal with the challenge of maintaining adequate control of perioperative blood pressure. On sudden elevations, a precise control is required to prevent end-organ damage. Recently, clevidipine, an ultra-short acting calcium antagonist has been approved by the FDA (www.accessdata.fda.gov), as a strategy for the intravenous treatment of hypertension; and by the Spanish Agency of Medicines and Medical Devices (www.aemps.gob.es) for the rapid reduction of arterial blood pressure in the perioperative setting. This medication has shown to have a rapid onset, easy titratability, and to exert a precise control of blood pressure. In addition, clevidipine has shown to be highly effective as monotherapy, and to have an excellent transition to oral antihypertensive therapy. For this article, an online search of the Medline literature was conducted up to February 2014 and "clevidipine" and "hypertension" used as keywords in order to analyze pharmacokinetics and pharmacodynamics of clevidipine. There are also clinical studies that provide evidence of the rapid and effective control that clevidipine has on blood pressure, especially in acute perioperative and emergency settings.
authors.affiliation: Departamento de Anestesiología, Wexner Medical Center, Ohio State University, Columbus, Ohio, Estados Unidos de Norteamérica.
authors.forename: A
authors.initials: A
authors.lastname: Zuleta-Alarcón
authors.affiliation: Departamento de Anestesiología, Wexner Medical Center, Ohio State University, Columbus, Ohio, Estados Unidos de Norteamérica.
authors.forename: K
authors.initials: K
authors.lastname: Castellón-Larios
authors.affiliation: Departamento de Anestesiología, Wexner Medical Center, Ohio State University, Columbus, Ohio, Estados Unidos de Norteamérica; Departamento de Neurocirugía, Wexner Medical Center, Ohio State University, Columbus, Ohio, Estados Unidos de Norteamérica. Electronic address: Sergio.Bergese@osumc.edu.
authors.forename: S
authors.initials: S
authors.lastname: Bergese
mesh_terms: D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002121:Calcium Channel Blockers; D011725:Pyridines; C118563:clevidipine
keywords: Agentes antihipertensivos; Antihypertensive agents; Bloqueadores de los canales de calcio; Calcium channel blockers; Clevidipine; Clevidipino; Crisis hipertensiva; Hipertensión arterial; Hypertension; Hypertensive crisis; Periodo perioperatorio; Perioperative period